---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-056415"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2025-06-23T23:59:59+00:00"
generated_at: "2026-05-18T23:29:24.081868+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CorMedix raises Q2 net sales guidance to $35-40M; LDO customer implements DefenCath with 50%+ more patients

## Summary
- LDO customer commenced ordering DefenCath; implementation targets at least 50% more patients than previously communicated.
- CorMedix amended existing agreement with LDO customer to reflect anticipated increased product use.
- Q2 2025 net sales guidance raised from $31M to $35-40M; modest revenue contribution expected in June with growth through H2 2025.
- CEO cites implementation will provide DefenCath access to thousands of adult patients at risk for catheter-related bloodstream infections.

## SEC filing metadata
- accession: 0001213900-25-056415
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2025-06-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390025056415/0001213900-25-056415-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390025056415/ea0246261-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-056415
- JSON: https://secwatch.observer/filing/0001213900-25-056415.json
- Plain text: https://secwatch.observer/filing/0001213900-25-056415.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.